Review Herpesviruses and Their Host Cells: A Successful Liaison

Barbara Adler,¹ Christine Sattler,² and Heiko Adler^{3,*}

During a long history of coevolution, herpesviruses have reached a fine-tuned balance with their hosts, allowing them to successfully persist and spread to new hosts without causing too much damage. Only under certain circumstances, as in neonates or immunocompromised individuals, they may cause serious diseases. The delicate balance between herpesviruses and their hosts results from interactions of a great variety of viral and cellular factors which together shape the tropism for a particular host, tissue, or cell. Understanding these interactions will provide insight into the viral life cycle and cell biology in general. Moreover, it will also facilitate comprehension of herpesvirus pathogenesis, enabling the development of new strategies to combat herpesviruses in cases where they cause disease.

Herpesviruses: A Strategy of 'Travel and Hide'

Primary herpesvirus infection generally results in a productive infection which is subsequently limited by the host immune response, leaving behind latently infected cells which persist in the host [\[1\]](#page-9-0). Latency can be defined as carriage of the virus genome in the absence of virus production but the ability of the virus to reactivate and to re-enter the lytic cycle. During latency, only restricted sets of viral genes are expressed and the viral genomes mostly persist as episomes in the nuclei of infected cells. In some cases, viral genomes can also integrate into the host genome.

During their life cycle, herpesviruses usually infect different cell types in various tissues. Subclassification of herpesviruses is partially based on their cell and tissue **tropism** (see [Glossary\)](#page-2-0). α -Herpesviruses, such as herpes simplex virus (HSV) or varicella zoster virus (VZV), become latent in cells of the nervous system. β -Herpesviruses, including human cytomegalovirus (HCMV), are characterized by a very broad cell tropism when productively infecting cells and become latent in progenitors of the hematopoietic cell system. γ -Herpesviruses, such as Epstein–Barr virus (EBV) or Kaposi sarcoma-associated herpesvirus (KSHV), show a more restricted cell tropism and are characterized by their ability to transform latently infected cells and induce tumors in their infected hosts.

Usually, the portal of entry for a specific herpesvirus is not the site of latency. Thus, the incoming virus has to travel to the site of latency using either migrating cells as vehicles for dissemination or, in the case of α -herpesviruses, cell protrusions of nerve cells. Often, reactivating virus also uses the same routes back to ensure horizontal spread from productively infected cells. Understanding the interplay of viral and host cell factors during the different phases of the viral life cycle will not only provide insights into disease pathogenesis but also be the basis for the development of new antiviral drugs and herpesvirus-based vaccine or gene-therapy vectors. For these reasons, herpesvirus infection of different cell and tissue types is an area of intensive research using established and new techniques or screening methods ([Table 1](#page-1-0)).

CellPress

Trends

Herpesvirus host cells are defined by their susceptibility to productive or latent infection.

Herpesvirus host cells contribute to navigation of viruses through the infected host, either directly as vehicles or indirectly by shaping the glycoprotein content of viral envelopes.

Herpesviruses can manipulate their host cells by changing their differentiation status.

Herpesviruses stand out by a highly redundant equipment with regulatory proteins or noncoding RNAs. This redundancy stands in the way of clearing a herpesvirus infection.

The development of new antiherpesviral drugs or vaccines, and the application of herpesviruses as oncolytic agents, vaccine- or gene-therapy vectors depends on understanding interactions between viral and host cell factors.

¹Max von Pettenkofer-Institute, Department of Virology, Ludwig-Maximilians-University Munich, Pettenkoferstraße 9A, D-80336 Munich, Germany ²Helmholtz Zentrum München – German Research Center for Environmental Health (GmbH), Institute of Lung Biology and Disease, Comprehensive Pneumology Center, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany ³Comprehensive Pneumology Center, Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München – German Research Center for Environmental Health (GmbH), Marchioninistrasse 25, D-81377 Munich, Germany, and University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany^{[4](#page-1-0)}

Trends in Microbiology

CellPress

Table 1. Methods and Techniques Used to Study the Interaction of Viral and Host Factors

4 Member of the German Center of Lung Research (DZL)

*Correspondence: h.adler@helmholtz-muenchen.de (H. Adler).

Herpesvirus Tropism: Factors Influencing Herpesvirus Infection of Different Cell and Tissue Types

An important concept for understanding the mechanisms of infection of different cell and tissue types is the concept of tropism. This concept has been comprehensively reviewed by Heise and Virgin [\[2\].](#page-9-0) Briefly, tropism is the capacity of a virus to infect specific cells, tissues or species, and is determined by both susceptibility and permissiveness. A host cell is susceptible if it has the proper receptor(s), allowing the virus to enter the cell, and it is permissive if it allows viral replication, that is, it supports productive infection. Thus, tropism is determined by many factors of both the virus and the host. Although essential for infection, passage through the cellular membrane barrier is just the first step to successful infection. Several events that occur after binding and entry exert profound effects on the further progress of the infection. For example, the host cell is armed with molecules which can directly inhibit viral replication, induce antiviral innate

RTICLE I

Trends in Microbiology

Cell^{ress}

immune responses or cell death. Viruses can establish productive infection only when they find ways to counteract these lines of defense. The large genomes of herpesviruses, which code for hundreds of different genes, provide a highly redundant pool of proteins and noncoding RNAs to neutralize and overcome these barriers.

Virus–host cell interactions are extremely fine-tuned: differentiation or transformation of a cell may completely abrogate infection or generate new permissive host cells. The same is true for latency establishment. Differentiation may favor a latent stage or lead to reactivation from latency. One rare side-effect of this virus–host cell interaction is the capability of γ -herpesviruses to establish a latent state of infection favoring outgrowth of host cells and tumor development.

In summary, viral and cellular factors shape the course and outcome of an infection, including the decision whether the virus undergoes lytic replication or enters latency [\(Figure 1,](#page-3-0) Key Figure). These factors can either act in all cells or only in particular cell types or in cells in a particular condition [\(Table 2\)](#page-4-0).

In the following sections, we discuss in more detail some selected examples of recent research of interactions between herpesviruses and host cellular factors.

Vehicles for Spread

Usually, host cells either become productively infected – and virus is spread to neighbouring cells – or a host-cell-dependent restriction of viral lytic genes and an induction of viral latent genes results in a nonproductive latent infection. There is also an in-between for herpesviruses. Herpesviruses use migrating host cells as vehicles to reach distant locations in their hosts. Usually, these cells are not overly permissive for the viral lytic cycle. Additionally, they are protected from virus-induced cell death and home to specific tissues. Virus replication in motile cells can, for example, be restricted by epigenetic regulation. Equine herpesvirus type 1 (EHV-1) replicates initially in epithelial cells but then infects monocytic cells for dissemination through the body. In these monocytic cells, EHV-1 replication is restricted and delayed, an effect which is mediated by histone deacetylases [\[3\].](#page-9-0) HCMV systemic spread is mediated by infection of circulating blood monocytes. To promote the survival of the infected monocytes, HCMV induces antiapoptotic proteins [4–[6\].](#page-9-0) Additionally, it has been shown that infection activates a proinflammatory state which favors migration to organs where the monocytes differentiate to longlived tissue macrophages which support the viral lytic cycle and thus establish infection in different organs [\[7\].](#page-9-0) Often, instead of infecting cells intrinsically programmed to migrate to sites of virus latency or reactivation, herpesvirus infection reprograms homing of host cells [\(Figure 2](#page-5-0)A): EBV, for example, infects naive B cells in the lymphoepithelium of the tonsils and transforms them by a specialized latency program to home to germinal centers, where they differentiate into memory B cells harboring a quiescent viral genome [\[8\]](#page-9-0). For VZV, it has been demonstrated that infection of T cells in tonsil lymphoid tissues remodels the surface of the infected T cells to enhance homing to skin sites of replication [\[9,10\].](#page-9-0) For murine cytomegalovirus (MCMV), it has been described that, in the peripheral blood of infected mice, only patrolling monocytes – but not inflammatory monocytes – are infected [\[11\]](#page-9-0). Under the aspect of a herpesvirus reprogramming, it will be of interest to find out whether MCMV programs monocytes to acquire a patrolling phenotype or whether it preferentially infects patrolling monocytes.

Herpesvirus Navigation

Herpesvirus spread can be the result of virus progeny randomly spreading infection from an infected cell to neighbouring host cells or transport through the bloodstream via infected cells, but it may also be the result of a host-cell-dependent virus modification addressing the virus progeny to specific host cells [\(Figure 2B](#page-5-0)). For EBV and HCMV, models of navigated virus spread have been studied in detail [\[12,13\].](#page-9-0) Both viruses code for alternative gH/gL glycoprotein

Glossary

Cre/loxP-system: a site-specific recombination system, consisting of the enzyme Cre recombinase and a pair of short target sequences, called loxP sites. Cre catalyzes DNA recombination between the loxP sites, and recombination between a pair of directly repeated loxP sites results in the deletion of the intervening DNA (the so-called floxed sequence)

Mass spectrometry: an analytical technique that ionizes chemical species and sorts the ions based on their mass-to-charge ratio. Proteomics: large-scale study of proteins.

RNA interference (RNAi): a

biological process in which RNA molecules inhibit gene expression. SILAC: stable isotope labeling with amino acids in cell culture. The technique is based on mass spectrometry that detects differences in protein abundance among samples using nonradioactive isotopic labeling. Cells are differentially labeled by growing them in medium either containing normal amino acids or amino acids labeled with stable, nonradioactive heavy isotopes. Metabolic incorporation of the amino acids into proteins results in a mass shift of the corresponding peptides. When two samples are combined. the relative protein abundance is reflected by the ratio of peak intensities in the mass spectrum.

Single-cell mass cytometry: a combination of flow cytometry and mass spectrometry, also called cytometry by time-of-flight (CyTOF). Tandem affinity purification (TAP): a purification technique for studying protein–protein interactions, applying a protein with a designed tag, the TAP tag.

Tropism: the capacity of a virus to infect or damage specific cells, tissues, or species.

Trends in Microbiology

CellPress

Key Figure

The Interplay of Viral and Host Factors Shapes the Course and Outcome of Infection

Herpesvirus-host cell interaction - important questions

Figure 1. A great variety of viral and cellular (host) factors influence the infection of cells or tissues during the different phases of the viral life cycle. They may facilitate or prevent infection and influence the decision whether the virus replicates lytically or enters latency.

Trends in Microbiology

CellPress

Table 2. Factors Influencing Cell and Tissue Tropism of Herpesviruses

complexes promoting recognition of specific host cell receptors. EBV particles released from epithelial cells predominantly contain trimeric gH/gL/gp42 complexes which recognize the B cell surface protein HLA class II and are directed toward infection of B cells. In B cells, the viral protein gp42 is retained and degraded, resulting in virus particles predominantly containing gp42 negative dimeric gH/gL complexes which promote entry into epithelial cells via integrin receptors [\[14\]](#page-10-0). Based on this, it has been proposed that latently infected memory B cells migrate to the lymphoepithelium of tonsils where they can differentiate to plasma cells and activate the EBV lytic cycle. Virus is then directed to neighbouring epithelial cells which produce B-cell-tropic virus for horizontal transmission to B cells in a new host [\[8,12\].](#page-9-0) Indeed, virus found in saliva of EBVinfected humans is gH/gL/gp42-rich [\[15\]](#page-10-0).

HCMV codes for a gH/gL/gO complex which drives infection of cells expressing platelet-derived growth factor receptor alpha (PDGFR- α) [\[16\]](#page-10-0), and for a gH/gL/pUL(128,130,131A) complex which drives infection of most PDGFR- α -negative cells through a still unknown receptor. In cell culture, fibroblasts infected with HCMV release virions with high or low amounts of gH/gL/pUL

Trends in Microbiology

CellPress

Trends in Microbiology

Figure 2. Infection Is Navigated by Virus Differentiating Its Host Cell and by Cells Shaping the Virus Surface. (A) Migrating cells which home to infected tissues (left side) become infected in the vicinity of their target tissues. Infection changes the cells' differentiation state, which drives homing of these newly infected cells to different target tissues (right side). (B) Different host cells differently shape the virion coat and thereby switch the viral cell tropism. Virus particles released from one cell type are thus targeted to a second cell type and vice versa.

(128,130,131A), a particle mixture which can readily infect all host cells of HCMV. Endothelial cells, in contrast, only release virions with low amounts of gH/gL/pUL(128,130,131A), which do not infect endothelial cells [\[13\].](#page-9-0) gH/gL/pUL(128,130,131A)-dependent cell-associated spread to neighbouring cells is possible from fibroblasts and endothelial cells. Thus, HCMV host cells shape the tropism of the virus which has to bridge long distances such as during horizontal transmission. Application of new techniques allows the ability to follow herpesvirus navigation in vivo. Direct cell contacts of infected and uninfected cells can be visualized by multiphoton intravital microscopy. To track the origin of virus traveling long distance, cell type-dependent labelling has been performed by infecting transgenic mice expressing cell type-specific cre with

IC L

Trends in Microbiology

viruses carrying lox-P-flanked reporter genes [\[17,18\]](#page-10-0). Virus navigation by employing the host cell machinery to shape the receptor-binding virion surface appears an efficient strategy of some herpesviruses to achieve directed, and if necessary, long-distance traveling to cells which are hideouts for latent virus, virus production sites, or first target cells in new hosts.

Latent or Lytic Cycle: The Host Cell Decides

After primary infection, the lifelong herpesvirus infection is characterized by virus persistence in a latent stage interrupted by sporadic periods of lytic replication. During lytic replication, infectious progeny is produced whereas, during latency, the viral genome remains 'silent' inside the infected host cell. The decision between lytic replication and latency is predominantly influenced by host cell factors.

Epigenetic Mechanisms

Epigenetic gene regulation is usually defined as heritable changes in the activity and expression of genes, caused by chromosomal changes, including DNA methylation, histone modifications, and nucleosome positioning, which do not alter the DNA sequence [\[19\].](#page-10-0) It has emerged only recently that both viral and host cell factors that are involved in epigenetic gene regulation play an important role in the regulation of herpesvirus latency. Consequently, the epigenetic regulation of infections by all classes of herpesviruses is an area of intensive research [20–[23\]](#page-10-0). Epigenetic regulation often is cell-type-specific, and thus, may also influence the decision between lytic or latent infection in a cell-type-specific manner. Here, we highlight some recent findings in the field: HSV undergoes lytic infection in epithelial cells while it establishes a latent infection in sensory neurons [\[23\]](#page-10-0). It has been shown that, in dividing cells like epithelial cells or fibroblasts, HSV DNA associates with histones within a few hours whereas in nondividing neurons, the association with histones and Polycomb proteins, a family of proteins involved in modification and remodeling of chromatin, takes much longer [\[24\]](#page-10-0). It has been speculated that this might be due to smaller pools of histones in nondividing neurons [\[23\].](#page-10-0) Differences in Polycomb proteins between subtypes of neurons are also discussed as factors influencing the anatomical preferences of HSV-1 for the orofacial region and of HSV-2 for the genital region [\[25\]](#page-10-0). In hematopoietic stem cells, HCMV latency is achieved by recruitment of KRAB-associated protein 1 (KAP1) together with heterochromatin protein 1 (HP1) and the histone methyltransferase SET domain, bifurcated 1 (SETDB1), to the viral genome which finally results in transcriptional silencing [\[26\]](#page-10-0). After reactivation, KAP1 remains associated with the viral genome but its heterochromatin-inducing activity is counteracted by phosphorylation mediated by the mammalian target of rapamycin (mTOR). CCCTC binding factor (CTCF) is a cellular DNA-binding protein important for the regulation of genomic chromatin boundaries, control of transcription, and long-range DNA interactions [\[27\].](#page-10-0) Together with the cohesin component Rad21, CTCF acts as a potent restriction factor for KSHV replication [\[28\].](#page-10-0) Knockdown of these proteins by siRNAs increased the production of infectious virus. As CTCF and cohesin contribute to cell-type-specific chromatin organization and function [\[29\],](#page-10-0) it would be highly interesting to see whether it affects virus infection in an equally cell-type-specific manner.

Cytokines

Already earlier studies have demonstrated a cell-type-specific regulation of gammaherpesvirus latency by interferon-gamma (IFN- γ) [\[30\].](#page-10-0) While macrophages were responsive to IFN- γ -mediated suppression of MHV-68 reactivation, B cells were not. Interleukin-21 (IL-21) is produced by T follicular helper cells and is important for the germinal center reaction and for the generation of long-lived plasma cells. MHV-68-infected B cells pass through the germinal center reaction to become latently infected [\[31\]](#page-10-0). Consequently, it has recently been shown that IL-21 is a critical factor for the efficient establishment of latency in B cells [\[32\].](#page-10-0) In IL-21R-deficient mice, that is, in the absence of IL-21 signaling, fewer infected spleen cells gained access to the germinal center B cell population, and the infected cells showed reduced expansion and reduced reactivation. It is likely

Cell^{ress}

ICILE

Trends in Microbiology

that this effect is specific for B cells and does not affect other latently infected cells like macrophages, although this has not yet been tested. New data demonstrate cell-type-dependent effects also for type I interferons (IFN-I). Using Mx1-cre mice to tag floxed MHV-68 genomes in IFN-I responding cells, Tan et al. [\[33\]](#page-10-0) demonstrated that the impact of IFN-I on viral replication was strongly cell-type-dependent. In epithelial cells, MHV-68 infection induced only a weak IFN-I response, allowing virus replication. In contrast, in macrophages and B cells, it induced a strong IFN-I response which suppressed replication in macrophages, but due to counteracting viral evasion mechanisms, not in B cells. Consequently, a shift from lytically infected macrophages to latently infected B cells was promoted. For HSV-1, new data have shown that neuronal IFN-I signaling is required to suppress viral replication and protect from pathogenesis [\[34\].](#page-10-0) IFN-driven innate responses in neural tissues were much more important than IFN-I signaling in the immune system and in peripheral tissues. However, whether this neuronal IFN-I signaling is also involved in

Cell Differentiation

The stage of differentiation or maturation of a cell may facilitate or prevent efficient infection. For HCMV, the most established link between cell differentiation and the decision to go latent or lytic is myeloid differentiation [\[35\].](#page-10-0) Progenitors of the myeloid lineage are hosts for latent HCMV, and differentiation to macrophages or dendritic cells results in reactivation of the virus. Recently, Berger et al. investigated the transition from restriction of HCMV infection in human embryonic stem cells (hESC) toward susceptibility in hESC-derived neural precursors [\[36\]](#page-10-0). Using protocols for controlled induction of differentiation of hESC into neural precursors, they discovered $PDGFR-\alpha$ as a determinant of HCMV susceptibility. For MHV-68, the transcription factors Blimp-1 and interferon regulatory factor 4 (IRF4) are both required for maintenance of MHV-68 latency and for virus reactivation [\[37,38\].](#page-10-0) Both factors promote plasma cell differentiation which is a prerequisite for reactivation of MHV-68 from B cells. Efficient reactivation, in turn, serves to renew the viral latency reservoirs.

the regulation of HSV latency is currently not clear and needs further investigation.

Latent or Lytic Cycle: The Role of Noncoding RNAs

Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), are produced by both host cells and herpesviruses. miRNAs are approximately 22-nucleotide long ncRNAs, which silence gene expression post-transcriptionally by binding to the 3' untranslated regions of target mRNAs [\[39\].](#page-10-0) Both cellular and viral miRNAs are predestined to cell-type-specifically influence infection of cells and tissues: (i) they can be expressed in a cell or tissue-type-specific manner or only at a particular time of the viral life cycle (spatiotemporal expression), and (ii) the abundance of target mRNAs might alter their effect [\[40\]](#page-10-0). For example, a neuron-specific host miRNA, miR-138, has been shown to repress expression of ICP0, the HSV-1 transactivator of lytic gene expression [\[41\].](#page-10-0) Thereby, miR-138 acts as a neuron-specific factor to promote host cell survival and HSV latency by repressing viral lytic replication. miR-155, a host miRNA mainly expressed in hematopoietic cells, is critical for reactivation of murine gammaherpesvirus 68 (MHV-68) from latency [\[42\]](#page-10-0). A KSHV long ncRNA called polyadenylated nuclear (PAN) RNA is essential for virion production [\[43\].](#page-10-0) It binds relocalized poly(A)-binding protein C1 (PABPC1) in KSHVinfected B cells and is required for the expression of late viral genes [\[44\].](#page-10-0) A highly abundant ncRNA of EBV, EBV-encoded RNA 2 (EBER2), localizes to specific regions of the viral genome and facilitates, through RNA–RNA interactions, the binding of the host transcription factor PAX5 [\[45\].](#page-10-0) This interaction seems to be necessary for efficient lytic replication since knockdown of EBER2 decreased lytic replication. A long ncRNA of HCMV (RNA4.9) represses transcription of lytic genes by interacting with components of the Polycomb repression complex and the major immediate early promoter, thereby most likely regulating latency in CD14-positive monocytes and CD34-positive hematopoietic cells [\[46\].](#page-10-0) Herpesvirus saimiri (HVS) U-rich RNA 1 (HSUR 1), an ncRNA expressed in HVS-infected T cells, was found to degrade host miR-27 in a sequence-specific and binding-dependent manner [\[47\]](#page-10-0). Murine cytomegalovirus

Cellress

Trends in Microbiology

(MCMV) also targets miR-27 for degradation by a similar antisense RNA-based mechanism [\[43\],](#page-10-0) and this activity has been shown to be important for efficient virus replication in vivo [\[48\].](#page-10-0)

Redundancy Can Overcome Host Restrictions

Herpesvirus genomes code for a large number of viral proteins which, in the majority of cases, are neither structural proteins nor needed for viral replication in cultured cells. Through interaction with cellular proteins, they can influence the biology of their host cells, for example, as immunoregulatory proteins which interfere with the innate or adaptive antiviral immune response, as antiapoptotic proteins or regulators of cellular antiapoptotic proteins, or as regulators of cellular transcription factors. Often, herpesviruses express a redundant pool of proteins with identical or overlapping functions. An example of redundant genomic structures are herpesviruses with more than one lytic origin of replication (oriLyt). OriLyts are defined sites on the viral genome where herpesvirus lytic DNA replication is initiated. While some herpesviruses, for example HCMV, have a single oriLyt, others such as MHV-68 have multiple oriLyts [\[49,50\]](#page-10-0). In a recent study, the role of the oriLyts of MHV-68 was examined [\[51\].](#page-10-0) The working hypothesis was that the presence of two oriLyts can overcome cell-type-specific restrictions of lytic replication by cellular proteins. Loss of either of the two oriLyts was well tolerated in some cell types while it resulted in reduced fitness in others. DNA-affinity purification in combination with mass spectrometry revealed distinct sets of cellular proteins interacting with the right oriLyt in different cell types. There were 193 proteins exclusively detected in extracts of TCMK-1 epithelial cells, and 37 proteins exclusively detected in extracts of NIH3T3 fibroblasts. For example, Hexim1 was found only in TCMK-1 cells while Rbbp4 was found only in NIH3T3 cells [\[51\]](#page-10-0). Functional assays showed that, in the absence of the left oriLyt, Hexim1 exerted an inhibitory effect on lytic replication in TCMK-1 but not in NIH3T3 cells. Consequently, downregulation of Hexim1 in TCMK-1 cells enhanced replication while upregulation of Hexim1 in NIH3T3 cells inhibited virus replication of this mutant. Thus, depending on the cellular host, overexpression and downregulation of Hexim1 either reduced or enhanced the replication of the mutant lacking the left oriLyt, indicating that Hexim1 is a rate-limiting cellular protein in a situation where only one oriLyt is present. However, the virus can overcome this restriction by the presence of two oriLyts, indicating that two oriLyts are an advantage for optimal virus fitness. Similarly, Rbbp4 supported

Trends in Microbiology

Figure 3. Redundancy Can Overcome Host Restrictions: Two Lytic Origins of Replication Are Better Than One. Cellular proteins may support (green) or inhibit (red) lytic replication originating at a given oriLyt. Thus, in situations where only one oriLyt is present (as indicated by the red x), cellular proteins may be rate limiting. The virus can overcome potential negative effects by the presence of two oriLyts.

CellPress

TICLE I

Trends in Microbiology

Cell^{ress}

lytic replication originating at the right oriLyt while it strongly inhibited lytic replication originating at the left oriLyt. Thus, Rbbp4, like Hexim1, was shown to be a rate-limiting cellular protein in situations where only one oriLyt is present. Again, the virus can overcome potential negative effects by the presence of two oriLyts. Taken together, these data suggested that the presence of multiple oriLyts enables herpesviruses which carry more than one oriLyt to efficiently replicate in the presence of varying sets of activating or inhibitory cellular proteins, thus assuring optimal fitness in different cell or tissue types [\(Figure 3\)](#page-8-0).

Concluding Remarks and Future Perspectives

Investigation of factors influencing herpesvirus infection of different cells and tissues will continue to be an area of intense research. Understanding virus–host cell interactions will result in new antiviral drugs directed against both viral and cellular targets, and, as virus research has always done, reveal new insights into cell biology. To fight herpesvirus infections, eliminating latent virus would be an invaluable milestone (see Outstanding Questions). Thus, strategies to either inhibit reactivation from latency ('locking in latency') [\[20,23\]](#page-10-0) or, the opposite approach, to induce reactivation and lytic replication ('forcing out of latency') are currently discussed [\[20,26\].](#page-10-0) Locking in latency might be valuable when reactivation from latency has the potential to harm the host, for example, reactivation of HSV in the peripheral or central nervous system [\[23\].](#page-10-0) Forcing out of latency by transient activation of HCMV lytic gene expression has been shown to enable killing of latently infected, that is, normally immunologically invisible cells, by cytotoxic T lymphocytes [\[52\],](#page-10-0) and has been suggested as a way to purge latently infected cells from HCMV-positive transplants by ex vivo treatment prior to engraftment [\[26\]](#page-10-0). The better we understand herpesvirus–host cell interactions, the more accurate our risk–benefit evaluations will become when applying herpesviruses as oncolytic agents [\[53,54\],](#page-10-0) and vectors for vaccination or tumor therapy [\[55,56\].](#page-10-0) Finally, any knowledge on herpesvirus–host cell interactions will contribute to the elaboration of the concept that herpesviruses, as constituents of the so-called virome, may shape the host immune response and even be beneficial for the host [\[57\]](#page-10-0).

Acknowledgments

The authors acknowledge all of their colleagues for their contributions. Our review is neither comprehensive nor complete, and we apologize to those whose work could not be cited. Work in the lab of B.A. was funded by grants from the Deutsche Forschungsgemeinschaft (AD131/3-3 and AD131/4-1), and work in the lab of H.A. was funded by grants from the Bundesministerium fuer Bildung und Forschung (NGFNplus, PIM-01GS0802-3), from the Wilhelm Sander-Stiftung (2009.046.1+2), and by intramural funding for Environmental Health Projects of the Helmholtz Zentrum München – German Research Center for Environmental Health (GmbH).

References

- 1. [Roizman, B. and Pellett, P.E. \(2001\) The family Herpesviridae: a](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0580) 7. Stevenson, E.V. et al. [\(2014\) HCMV reprogramming of infected](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0610) brief introduction. In Fields – Virology [\(4th edn\) \(Knipe, D.M.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0580) et al., eds), pp. 2381–[2397, Lippincott Williams & Wilkins](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0580)
- 2. [Heise, M.T. and Virgin, H.W. \(2013\) Pathogenesis of viral infec-](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0585)8. [Thorley-Lawson, D.A. \(2015\) EBV Persistence](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0615) introducing the tion. In Fields – Virology [\(6th edn\) \(Knipe, D.M.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0585) et al., eds), pp. 254–[285, Lippincott Williams & Wilkins](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0585)
- 3. Laval, K. et al. [\(2015\) Equine herpesvirus type 1 replication is](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0590) [delayed in CD172a+ monocytic cells and controlled by histone](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0590) [deacetylases.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0590) J. Gen. Virol. 96, 118–130
- 4. Reeves, M.B. et al. [\(2012\) Human cytomegalovirus activation](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0595) [of ERK and myeloid cell leukemia-1 protein correlates with](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0595) [survival of latently infected cells.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0595) Proc. Natl. Acad. Sci. U.S.A. 11. Daley-Bauer, L.P. et al. [\(2014\) Cytomegalovirus hijacks](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0630) [109, 588](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0595)–593
- 5. Collins-McMillen, D. et al. [\(2015\) Human cytomegalovirus](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0600) [promotes survival of infected monocytes via a distinct tem](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0600)[poral regulation of cellular Bcl-2 family proteins.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0600) J. Virol. 90, 12. [Hutt-Fletcher, L.M. \(2007\) Epstein](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0635)–Barr virus entry. J. Virol. 81, 2356–[2371](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0600)
- 6. Peppenelli, M.A. et al. [\(2016\) Human cytomegalovirus stimulates](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0605) 13. Scrivano, L. et al. [\(2011\) HCMV spread and cell tropism are](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0640) [the synthesis of select Akt-dependent antiapoptotic proteins](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0605) [during viral entry to promote survival of infected monocytes.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0605) J. Virol. [90, 3138](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0605)–3147
- [monocyte survival and differentiation: a Goldilocks phenomenon.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0610) [Viruses](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0610) 6, 782–807
- virus. [Curr. Top. Microbiol. Immunol.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0615) 390, 151–209
- 9. Sen, N. et al. [\(2015\) Single cell mass cytometry reveals remod](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0620)[eling of human T cell phenotypes by varicella zoster virus.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0620) Methods [90, 85](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0620)–94
- 10. [Sen, N. and Arvin, A.M. \(2016\) Dissecting the molecular mecha](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0625)[nisms of the tropism of varicella-zoster virus for human T cells.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0625) J. Virol. [90, 3284](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0625)–3287
- [CX3CR1\(hi\) patrolling monocytes as immune-privileged](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0630) [vehicles for dissemination in mice.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0630) Cell Host Microbe 15, [351](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0630)–362
- 7825–[7832](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0635)
- [determined by distinct virus populations.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0640) PLoS. Pathog. 7, [e1001256](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0640)

Outstanding Questions

Is redundancy or latency, or a combination of both, the secret of success of a herpesvirus infection?

It is possible to treat a herpesvirus infection, but will it be possible to cure it and also remove latent virus?

Are latent herpesviruses key players of human or animal viromes?

Trends in Microbiology

CellPress

- 14. Chesnokova, L.S. et al. [\(2009\) Fusion of epithelial cells by](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0645) Epstein–[Barr virus proteins is triggered by binding of viral glyco](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0645)proteins gHgL to integrins alphaybeta6 or alphaybeta8. Proc. [Natl. Acad. Sci. U.S.A.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0645) 106, 20464–20469
- 15. Jiang, R. et al. (2006) Epstein–[Barr virus shed in saliva is high in](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0650) [B-cell-tropic glycoprotein gp42.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0650) J. Virol. 80, 7281–7283
- 16. Kabanova, A. et al. [\(2016\) Platelet-derived growth factor-alpha](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0655) [receptor is the cellular receptor for human cytomegalovirus](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0655) [gHgLgO trimer.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0655) Nat. Microbiol. 1, 16082
- 17. Sacher, T. et al. [\(2008\) The major virus-producing cell type during](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0660) [murine cytomegalovirus infection, the hepatocyte, is not the](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0660) [source of virus dissemination in the host.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0660) Cell Host Microbe 3, [263](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0660)–272
- 18. Sacher, T. et al. [\(2011\) Shedding light on the elusive role of](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0665) [endothelial cells in cytomegalovirus dissemination.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0665) PLoS. Pathog. [7, e1002366](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0665)
- 19. Paluch, B.E. et al. [\(2016\) Epigenetics: A primer for clinicians.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0670) [Blood Rev.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0670) 30, 285–295
- 20. [Lieberman, P.M. \(2016\) Epigenetics and genetics of viral latency.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0675) [Cell Host Microbe](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0675) 19, 619–628
- 21. [Tempera, I. and Lieberman, P.M. \(2014\) Epigenetic regulation of](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0680) [EBV persistence and oncogenesis.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0680) Semin. Cancer Biol. 26, 22–29
- 22. [Kumar, A. and Herbein, G. \(2014\) Epigenetic regulation of human](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0685) [cytomegalovirus latency: an update.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0685) Epigenomics 6, 533–546
- 23. [Knipe, D.M. \(2015\) Nuclear sensing of viral DNA, epigenetic](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0690) [regulation of herpes simplex virus infection, and innate immunity.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0690) Virology [479-480, 153](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0690)–159
- 24. Cliffe, A.R. et al. [\(2013\) Kinetics of facultative heterochromatin](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0695) [and polycomb group protein association with the herpes simplex](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0695) [viral genome during establishment of latent infection.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0695) MBio 4, [e00590](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0695)–e612
- 25. Watson, Z. et al. [\(2013\) Role of polycomb proteins in regulating](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0700) [HSV-1 latency.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0700) Viruses 5, 1740–1757
- 26. Rauwel, B. et al. [\(2015\) Release of human cytomegalovirus from](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0705) latency by a KAP1/TRIM28 phosphorylation switch, eLife 4, [e06068](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0705)
- 27. [Pentland, I. and Parish, J.L. \(2015\) Targeting CTCF to control](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0710) [virus gene expression: a common theme amongst diverse DNA](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0710) viruses. Viruses [7, 3574](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0710)–3585
- 28. Li, D.J. et al. [\(2014\) CTCF and Rad21 act as host cell restriction](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0715) [factors for Kaposi's sarcoma-associated herpesvirus \(KSHV\) lytic](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0715) [replication by modulating viral gene transcription.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0715) PLoS Pathog. [10, e1003880](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0715)
- 29. Hou, C. et al. (2010) Cell type specifi[city of chromatin organiza](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0720)[tion mediated by CTCF and cohesin.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0720) Proc. Natl. Acad. Sci. U.S. A. [107, 3651](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0720)–3656
- 30. Steed, A. et al. [\(2007\) Gamma interferon blocks gammaherpes](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0725)[virus reactivation from latency in a cell type-speci](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0725)fic manner. J. Virol. [81, 6134](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0725)–6140
- 31. Frederico, B. et al. [\(2014\) A murid gamma-herpesvirus exploits](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0730) [normal splenic immune communication routes for systemic](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0730) spread. [Cell Host Microbe](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0730) 15, 457–470
- 32. [Collins, C.M. and Speck, S.H. \(2015\) Interleukin 21 signaling in B](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0735) cells is required for effi[cient establishment of murine gammaher](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0735)[pesvirus latency.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0735) PLoS Pathog. 11, e1004831
- 33. Tan, C.S. et al. [\(2016\) Type I interferons direct gammaherpesvi](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0740)[rus host colonization.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0740) PLoS Pathog. 12, e1005654
- 34. [Rosato, P.C. and Leib, D.A. \(2015\) Neuronal interferon signaling](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0745) [is required for protection against herpes simplex virus replication](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0745) [and pathogenesis.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0745) PLoS Pathog. 11, e1005028
- 35. [Sinclair, J.H. and Reeves, M.B. \(2013\) Human cytomegalovirus](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0750) [manipulation of latently infected cells.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0750) Viruses 5, 2803–2824
- 36. Berger, A.A. et al. [\(2015\) Transition toward human cytomegalo](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0755)[virus susceptibility in early human embryonic stem cell-derived](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0755) [neural precursors.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0755) J. Virol. 89, 11159–11164
- 37. Matar, C.G. et al. [\(2014\) Murine gammaherpesvirus 68 reactiva](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0760)[tion from B cells requires IRF4 but not XBP-1.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0760) J. Virol. 88, 11600– [11610](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0760)
- 38. Siegel, A.M. et al. [\(2010\) Blimp-1-dependent plasma cell differ](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0765)entiation is required for effi[cient maintenance of murine gamma](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0765)[herpesvirus latency and antiviral antibody responses.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0765) *J. Virol.* 84, [674](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0765)–685
- 39. Eulalio, A. et al. [\(2008\) Getting to the root of miRNA-mediated](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0770) [gene silencing.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0770) Cell 132, 9–14
- 40. Arvey, A. et al. [\(2010\) Target mRNA abundance dilutes micro-](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0775)[RNA and siRNA activity.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0775) Mol. Syst. Biol. 6, 363
- 41. Pan, D. et al. (2014) A neuron-specifi[c host microRNA targets](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0780) [herpes simplex virus-1 ICP0 expression and promotes latency.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0780) [Cell Host Microbe](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0780) 15, 446–456
- 42. Crepeau, R.L. et al. [\(2016\) miR-155 is necessary for ef](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0785)ficient [gammaherpesvirus reactivation from latency, but not for latency](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0785) [establishment.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0785) J. Virol. 90, 7811–7821
- 43. Tycowski, K.T. et al. [\(2015\) Viral noncoding RNAs: more sur](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0790)prises. [Genes Dev.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0790) 29, 567–584
- 44. Borah, S. et al. [\(2011\) A viral nuclear noncoding RNA binds re](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0795)[localized poly\(A\) binding protein and is required for late KSHV](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0795) [gene expression.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0795) PLoS Pathog. 7, e1002300
- 45. Lee, N. et al. [\(2015\) EBV noncoding RNA binds nascent RNA to](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0800) [drive host PAX5 to viral DNA.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0800) Cell 160, 607–618
- 46. Rossetto, C.C. et al. [\(2013\) Cis and trans acting factors involved](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0805) [in human cytomegalovirus experimental and natural latent infec](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0805)[tion of CD14 \(+\) monocytes and CD34 \(+\) cells.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0805) PLoS Pathog. 9, [e1003366](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0805)
- 47. Cazalla, D. et al. [\(2010\) Down-regulation of a host microRNA by a](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0810) [Herpesvirus saimiri noncoding RNA.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0810) Science 328, 1563–1566
- 48. Marcinowski, L. et al. [\(2012\) Degradation of cellular mir-27 by a](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0815) [novel, highly abundant viral transcript is important for ef](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0815)ficient [virus replication in vivo.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0815) PLoS Pathog. 8, e1002510
- 49. Roizman, B. et al. [\(2007\) Herpes simplex viruses. In](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0820) Fields -Virology [\(5th edn\) \(Knipe, D.M.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0820) et al., eds), pp. 2501–2601, [Lippincott Williams & Wilkins](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0820)
- 50. [Mocarski, J. \(2007\) Comparative analysis of herpesvirus-com](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0825)mon proteins. In [Human Herpesviruses: Biology, Therapy, and](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0825) Immunoprophylaxis (Arvin, A.M. et al.[, eds\), p. 44, Cambridge](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0825) [University Press](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0825)
- 51. Sattler, C. et al. [\(2016\) Multiple lytic origins of replication are](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0830) [required for optimal gammaherpesvirus](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0830) fitness in vitro and in vivo. PLoS Pathog. [12, e1005510](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0830)
- 52. Krishna, B.A. et al. [\(2016\) Transient activation of human cyto](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0835)[megalovirus lytic gene expression during latency allows cytotoxic](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0835) [T cell killing of latently infected cells.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0835) Sci. Rep. 6, 24674
- 53. Menotti, L. et al. [\(2012\) The molecular basis of herpesviruses as](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0840) oncolytic agents. [Curr. Pharm. Biotechnol.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0840) 13, 1795–1803
- 54. Campadelli-Fiume, G. et al. [\(2011\) Rethinking herpes simplex](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0845) [virus: the way to oncolytic agents.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0845) Rev. Med. Virol. 21, 213–226
- 55. [Barouch, D.H. and Picker, L.J. \(2014\) Novel vaccine vectors for](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0850) HIV-1. [Nat. Rev. Microbiol.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0850) 12, 765-771
- 56. [Glorioso, J.C. \(2014\) Herpes simplex viral vectors: late bloomers](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0855) [with big potential.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0855) Hum. Gene Ther. 25, 83-91
- 57. [Virgin, H.W. \(2014\) The virome in mammalian physiology and](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0860) disease. Cell [157, 142](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0860)–150
- 58. Zaman, A. et al. [\(2013\) Kaposi's sarcoma: a computational](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0865) [approach through protein-protein interaction and gene regula](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0865)[tory networks analysis.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0865) Virus Genes 46, 242–254
- 59. Li, Q. et al. [\(2015\) THY-1 cell surface antigen \(CD90\) has an](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0870) [important role in the initial stage of human cytomegalovirus](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0870) Infection. PLoS Pathog. [11, e1004999](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0870)
- 60. Griffiths, S.J. et al. [\(2013\) A systematic analysis of host factors](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0875) [reveals a Med23-interferon-lambda regulatory axis against her](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0875)[pes simplex virus type 1 replication.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0875) PLoS Pathog. 9, e1003514
- 61. Griffi[ths, S.J. \(2013\) Screening for host proteins with pro- and](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0880) [antiviral activity using high-throughput RNAi.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0880) Methods Mol. Biol. [1064, 71](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0880)–90
- 62. Li, R. et al. [\(2015\) Phosphoproteomic pro](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0885)filing reveals Epstein-[Barr virus protein kinase integration of DNA damage response](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0885) [and mitotic signaling.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0885) PLoS Pathog. 11, e1005346
- 63. Sato, Y. et al. [\(2016\) Cellular transcriptional coactivator RanBP10](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0890) [and herpes simplex virus 1 ICP0 interact and synergistically](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0890) [promote viral gene expression and replication.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0890) J. Virol. 90, 3173–[3186](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0890)
- 64. Weekes, M.P. et al. [\(2014\) Quantitative temporal viromics: an](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0895) [approach to investigate host](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0895)–pathogen interaction. Cell 157, [1460](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0895)–1472

Trends in Microbiology

- 65. [Baquero-Perez, B. and Whitehouse, A. \(2015\) Hsp70 isoforms](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0900) [are essential for the formation of Kaposi's sarcoma-associated](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0900) [herpesvirus replication and transcription compartments.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0900) PLoS Pathog. [11, e1005274](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0900)
- 66. Sacher, T. et al. [\(2008\) Conditional gene expression systems to](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0905) 91. Murata, T. et al. [\(2013\) Contribution of myocyte enhancer factor 2](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1030) [study herpesvirus biology in vivo.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0905) Med. Microbiol. Immunol. 197, [269](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0905)–276
- 67. Campadelli-Fiume, G. et al. [\(2012\) Viral and cellular contribu](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0910)[tions to herpes simplex virus entry into the cell.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0910) Curr. Opin. Virol. [2, 28](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0910)–36
- 68. [Gardner, T.J. and Tortorella, D. \(2016\) Virion glycoprotein-medi](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0915)[ated immune evasion by human cytomegalovirus: a sticky virus](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0915) makes a slick getaway. [Microbiol. Mol. Biol. Rev.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0915) 80, 663–677
- 69. [Heldwein, E.E. \(2016\) gH/gL supercomplexes at early stages of](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0920) [herpesvirus entry.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0920) Curr. Opin. Virol. 18, 1-8
- 70. Banerjee, S. et al. [\(2016\) The modulation of apoptotic pathways](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0925) [by gammaherpesviruses.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0925) Front. Microbiol. 7, 585
- 71. Laura, M.V. et al. [\(2015\) KSHV latent protein LANA2 inhibits](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0930) sumo2 modifi[cation of p53.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0930) Cell Cycle 14, 277–282
- 72. Sifford, J.M. et al. [\(2015\) Murine gammaherpesvirus 68 LANA](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0935) [and SOX homologs counteract ATM-driven p53 activity during](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0935) [lytic viral replication.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0935) J. Virol. 90, 2571–2585
- 73. Taylor, K.E. et al. [\(2014\) Novel roles of cytoplasmic ICP0: pro](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0940)[teasome-independent functions of the RING](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0940) finger are required [to block interferon-stimulated gene production but not to pro](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0940)[mote viral replication.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0940) J. Virol. 88, 8091–8101
- 74. Zenner, H.L. et al. [\(2013\) Herpes simplex virus 1 counteracts](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0945) [tetherin restriction via its virion host shutoff activity.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0945) J. Virol. 87, 13115–[13123](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0945)
- 75. Zhang, G. et al. [\(2016\) Cytoplasmic isoforms of Kaposi sarcoma](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0950) [herpesvirus LANA recruit and antagonize the innate immune DNA](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0950) sensor cGAS. [Proc. Natl. Acad. Sci. U.S.A.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0950) 113, E1034-E1043
- 76. Kumari, P. et al. [\(2015\) Herpesviruses: interfering innate immunity](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0955) [by targeting viral sensing and interferon pathways.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0955) Rev. Med. Virol. [25, 187](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0955)–201
- 77. Sun, C. et al. [\(2015\) Evasion of innate cytosolic DNA sensing by a](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0960) [gammaherpesvirus facilitates establishment of latent infection.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0960) J. Immunol. [194, 1819](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0960)–1831
- 78. Feng, P. et al. [\(2013\) Evasion of adaptive and innate immune](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0965) [response mechanisms by gamma-herpesviruses.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0965) Curr. Opin. Virol. [3, 285](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0965)–295
- 79. Nascimento, R. et al. [\(2012\) Virus manipulation of cell cycle.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0970) [Protoplasma](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0970) 249, 519–528
- 80. Wei, F. et al. [\(2016\) Cell cycle regulatory functions of the KSHV](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0975) [oncoprotein LANA.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0975) Front. Microbiol. 7, 334
- 81. Johnson, K.E. et al. [\(2014\) IFI16 restricts HSV-1 replication by](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0980) [accumulating on the hsv-1 genome, repressing HSV-1 gene](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0980) [expression, and directly or indirectly modulating histone mod](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0980)ifications. PLoS Pathog. [10, e1004503](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0980)
- 82. Chan, G. et al. [\(2012\) Human cytomegalovirus induction of a](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0985) [unique signalsome during viral entry into monocytes mediates](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0985) [distinct functional changes: a strategy for viral dissemination.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0985) J. [Leukoc. Biol.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0985) 92, 743–752
- 83. [Chan, Y.K. and Gack, M.U. \(2016\) Viral evasion of intracellular](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0990) [DNA and RNA sensing.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0990) Nat. Rev. Microbiol. 14, 360-373
- 84. [Luecke, S. and Paludan, S.R. \(2015\) Innate recognition of alpha](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0995)[herpesvirus DNA.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref0995) Adv. Virus Res. 92, 63–100
- 85. Caffarelli, N. et al. [\(2013\) Cyclin A degradation by primate cyto](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1000)[megalovirus protein pUL21a counters its innate restriction of](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1000) [virus replication.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1000) PLoS Pathog. 9, e1003825
- 86. [Spector, D.H. \(2015\) Human cytomegalovirus riding the cell](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1005) cycle. [Med. Microbiol. Immunol.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1005) 204, 409–419
- 87. Austgen, K. et al. [\(2012\) Multiple defects, including premature](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1010) [apoptosis, prevent Kaposi's sarcoma-associated herpesvirus](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1010) [replication in murine cells.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1010) J. Virol. 86, 1877–1882
- 88. [Jurak, I. and Brune, W. \(2006\) Induction of apoptosis limits](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1015) [cytomegalovirus cross-species infection.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1015) EMBO J. 25, 2634– [2642](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1015)
- 89. Keyes, L.R. et al. [\(2012\) Cyclophilin A is required for ef](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1020)ficient human cytomegalovirus DNA replication and reactivation, J. Gen. Virol. [93, 722](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1020)–732
- 90. Lee, S.H. et al. (2012) BcIAF1 restriction factor is neutralized by [proteasomal degradation and microRNA repression during human](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1025) cytomegalovirus infection. [Proc. Natl. Acad. Sci. U.S.A.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1025) 109, [9575](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1025)–9580
- family transcription factors to BZLE1 expression in Epstein–Barr [virus reactivation from latency.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1030) J. Virol. 87, 10148–10162
- 92. Zhou, G. et al. [\(2013\) The role of the CoREST/REST repressor](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1035) [complex in herpes simplex virus 1 productive infection and in](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1035) latency. Viruses [5, 1208](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1035)–1218
- 93. Roizman, B. et al. [\(2011\) Checkpoints in productive and latent](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1040) [infections with herpes simplex virus 1: conceptualization of the](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1040) issues. [J. Neurovirol.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1040) 17, 512–517
- 94. Gunther, T. et al. (2014) Infl[uence of ND10 components on](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1045) [epigenetic determinants of early KSHV latency establishment.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1045) PLoS Pathog. [10, e1004274](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1045)
- 95. Wagenknecht, N. et al. [\(2015\) Contribution of the major ND10](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1050) [proteins PML, hDaxx and Sp100 to the regulation of human](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1050) [cytomegalovirus latency and lytic replication in the monocytic](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1050) [cell line THP-1.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1050) Viruses 7, 2884–2907
- 96. [Kim, Y.E. and Ahn, J.H. \(2015\) Positive role of promyelocytic](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1055) [leukemia protein in type I interferon response and its regulation by](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1055) [human cytomegalovirus.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1055) PLoS Pathog. 11, e1004785
- 97. Sun, R. et al. [\(2014\) Kaposi's sarcoma-associated herpesvirus](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1060)[encoded LANA interacts with host KAP1 to facilitate establish](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1060)[ment of viral latency.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1060) J. Virol. 88, 7331–7344
- 98. Moser, J.M. et al. [\(2005\) Role of B-cell proliferation in the estab](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1065)[lishment of gammaherpesvirus latency.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1065) J. Virol. 79, 9480–9491
- 99. [Rosato, P.C. and Leib, D.A. \(2015\) Neurons versus herpes](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1070) [simplex virus: the innate immune interactions that contribute](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1070) [to a host-pathogen standoff.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1070) Future Virol. 10, 699–714
- 100. Park, S. et al. [\(2016\) Autophagy genes enhance murine gam](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1075)[maherpesvirus 68 reactivation from latency by preventing](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1075) [virus-induced systemic in](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1075)flammation. Cell Host Microbe 19, 91–[101](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1075)
- 101. McFadden, K. et al. [\(2016\) Metabolic stress is a barrier to](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1080) Epstein–[Barr virus-mediated B-cell immortalization.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1080) Proc. Natl. [Acad. Sci. U.S.A.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1080) 113, E782–E790
- 102. Huffmaster, N.J. et al. [\(2015\) Dynamic ubiquitination drives her](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1085)pesvirus neuroinvasion. [Proc. Natl. Acad. Sci. U.S.A.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1085) 112, [12818](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1085)–12823
- 103. Greene, W. et al. [\(2012\) The ubiquitin/proteasome system medi](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1090)ates entry and endosomal traffi[cking of Kaposi's sarcoma-asso](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1090)[ciated herpesvirus in endothelial cells.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1090) PLoS Pathog. 8, [e1002703](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1090)
- 104. Sato, Y. et al. (2016) Ubiquitin-specifi[c protease 9X in host cells](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1095) [interacts with herpes simplex virus 1 ICP0.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1095) J. Vet. Med. Sci. 78, [405](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1095)–410
- 105. Hughes, D.J. et al. [\(2015\) NEDDylation is essential for Kaposi's](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1100) [sarcoma-associated herpesvirus latency and lytic reactivation](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1100) [and represents a novel anti-KSHV target.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1100) PLoS Pathog. 11, [e1004771](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1100)
- 106. Sloan, E. et al. [\(2015\) Analysis of the SUMO2 Proteome during](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1105) [HSV-1 Infection.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1105) PLoS Pathog. 11, e1005059
- 107. Brown, J.R. et al. [\(2016\) SUMO ligase protein inhibitor of acti](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1110)[vated STAT1 \(PIAS1\) is a constituent promyelocytic leukemia](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1110) [nuclear body protein that contributes to the intrinsic antiviral](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1110) [immune response to herpes simplex virus 1.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1110) J. Virol. 90, 5939–[5952](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1110)
- 108. McKinney, C. et al. [\(2013\) A new role for the cellular PABP](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1115) [repressor Paip2 as an innate restriction factor capable of limit](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1115)[ing productive cytomegalovirus replication.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1115) Genes Dev. 27, [1809](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1115)–1820
- 109. Strang, B.L. et al. [\(2012\) Host cell nucleolin is required to maintain](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1120) [the architecture of human cytomegalovirus replication compart](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1120)ments. MBio [3, e00301](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1120)–e00311
- 110. Cheng, F. et al. [\(2016\) Suppression of Kaposi's sarcoma-asso](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1125)[ciated herpesvirus infection and replication by 5](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1125)'-AMP-activated [protein kinase.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1125) J. Virol. 90, 6515–6525
- 111. Xu, S. et al. [\(2016\) Expression of oncogenic alleles induces](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1130) [multiple blocks to human cytomegalovirus infection.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1130) J. Virol. [90, 4346](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1130)–4356

CellPress

PRE A RT CLE

Trends in Microbiology

[replication.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1140) J. Virol. 87, 9323–9332

- 748–[754](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1135)
- 112. Leidal, A.M. et al. [\(2012\) Evasion of oncogene-induced](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1135) 114. Maruzuru, Y. et al. (2016) p53 is a host cell regulator during
[senescence by gammaherpesviruses.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1135) Curr. Opin. Virol. 2, berpes simplex encephalitis. J. Virol.
- 113. Maruzuru, Y. et al. [\(2013\) Roles of p53 in herpes simplex virus 1](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1140) 115. Liu, Y. et al. [\(2015\) Tetherin restricts HSV-2 release and is](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1150) [counteracted by multiple viral glycoproteins.](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1150) Virology 475, 96–[109](http://refhub.elsevier.com/S0966-842X(16)30186-X/sbref1150)